• Larimar Therapeutics will present three nomlabofusp posters at the International Congress for Ataxia Research in Atlanta on November 12, 2026.
• Presentations will include previously disclosed interim clinical data from an ongoing open-label study of long-term daily treatment in patients with Friedreich's ataxia.
• New analyses will examine plasma lipid profiles and gene expression responses to nomlabofusp treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051605PRIMZONEFULLFEED9871593) on November 05, 2026, and is solely responsible for the information contained therein.